This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Baxter Reports Results Of ADVATE Real-World Experience From Worldwide Post-Marketing Database Of Hemophilia A Patients

Stocks in this article: BAX

Baxter International Inc. (NYSE:BAX) today presented two comprehensive analyses supporting the proven clinical and real-world results of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] during the 24 th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The presentations include two complementary studies of the ADVATE profile, including an analysis of post-marketing data from approximately 1,200 hemophilia A patients across 15 countries as well as safety findings from a 10-year database of 12 clinical trials.

A meta-analysis of post-authorization safety studies (PASS) (abstract# PO148) presented at ISTH supports the overall product safety and effectiveness profile, as well as low rate of inhibitor development with ADVATE, with only one de-novo inhibitor in severe previously-treated patients (n=669) with more than 150 prior exposure days. 1 The analysis assessed the effectiveness of ADVATE treatment in non-controlled, real-world clinical practice, and found that the median annual bleed rate (ABR) for patients on continuous prophylaxis (twice a week or more, n=560) was 1.67, which supports the ABR reported in controlled clinical studies. 2 The effectiveness result in the study captured ADVATE efficacy in routine clinical practice (as opposed to efficacy, which measures in a controlled, interventional trial setting). The meta-analysis included patients from the United States, Australia, Japan, and 12 countries in Europe, who were followed for more than one year with exposure to ADVATE ranging between 85 and 103 mean exposure days across five studies. 1

''This meta-analysis of the post-market surveillance database, the largest available in hemophilia today, demonstrates a global patient experience with ADVATE that is consistent with the results reported in our highly controlled clinical programs,'' said Bruce Ewenstein, M.D., Ph.D., vice president of clinical affairs for Baxter. ''Given the broad range of patients and hemophilia clinical practice around the world, it is significant that these data continue to support the low inhibitor rate among patients using ADVATE as well as the effectiveness of bleed prevention when on an ADVATE prophylaxis regimen.''

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs